SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-23-112178
Filing Date
2023-10-27
Accepted
2023-10-27 16:15:31
Documents
13
Period of Report
2023-10-25
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2329328d1_8k.htm   iXBRL 8-K 25815
2 EXHIBIT 17.1 tm2329328d1_ex17-1.htm EX-17.1 2671
  Complete submission text file 0001104659-23-112178.txt   201382

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA srne-20231025.xsd EX-101.SCH 3051
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE srne-20231025_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE srne-20231025_pre.xml EX-101.PRE 22383
7 EXTRACTED XBRL INSTANCE DOCUMENT tm2329328d1_8k_htm.xml XML 3208
Mailing Address 4955 DIRECTORS PLACE SAN DIEGO CA 92121
Business Address 4955 DIRECTORS PLACE SAN DIEGO CA 92121 858-203-4100
Sorrento Therapeutics, Inc. (Filer) CIK: 0000850261 (see all company filings)

IRS No.: 330344842 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36150 | Film No.: 231355701
SIC: 2836 Biological Products, (No Diagnostic Substances)